QNCX Logo

Quince Therapeutics, Inc. (QNCX) 

NASDAQ
Market Cap
$63.18M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
162 of 776
Rank in Industry
101 of 433

Largest Insider Buys in Sector

QNCX Stock Price History Chart

QNCX Stock Performance

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August …

Insider Activity of Quince Therapeutics, Inc.

Over the last 12 months, insiders at Quince Therapeutics, Inc. have bought $330,905 and sold $0 worth of Quince Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Quince Therapeutics, Inc. have bought $656,733 and sold $1,834 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lamond David (director) — $167,913. Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) — $107,375. Ryan Charles S. (PRESIDENT) — $62,903.

The last purchase of 77,000 shares for transaction amount of $53,900 was made by Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) on 2024‑08‑30.

List of Insider Buy and Sell Transactions, Quince Therapeutics, Inc.

2024-08-30PurchaseCEO AND CHIEF MEDICAL OFFICER
77,000
0.1802%
$0.70$53,900+11.43%
2024-08-29PurchaseCEO AND CHIEF MEDICAL OFFICER
77,500
0.1782%
$0.69$53,475+10.63%
2024-08-21PurchaseCHIEF BUSINESS OFFICER AND COO
30,845
0.0698%
$0.63$19,337+17.19%
2024-08-20PurchaseCHIEF BUSINESS OFFICER AND COO
5,924
0.0136%
$0.60$3,579+21.72%
2024-08-20PurchasePRESIDENT
48,387
0.1191%
$0.65$31,452+21.72%
2024-08-19PurchaseCHIEF BUSINESS OFFICER AND COO
2,155
0.0047%
$0.58$1,250+20.49%
2023-12-14Purchasedirector
22,627
0.0528%
$1.04$23,532-4.81%
2023-12-13Purchasedirector
22,627
0.0528%
$1.00$22,627-0.97%
2023-12-12Purchasedirector
22,627
0.0544%
$1.02$23,074-0.68%
2023-12-07Purchasedirector
19,123
0.0446%
$1.01$19,314-1.40%
2023-12-06Purchasedirector
19,123
0.0455%
$1.02$19,505-0.38%
2023-12-05Purchasedirector
19,123
0.0466%
$1.01$19,314+1.48%
2023-12-01Purchasedirector
14,378
0.033%
$0.94$13,515+4.44%
2023-11-30Purchasedirector
14,378
0.035%
$0.90$12,940+15.19%
2023-11-29Purchasedirector
14,378
0.035%
$0.98$14,090+5.31%
2023-08-31Purchasedirector
41,026
0.1136%
$1.32$54,154-21.37%
2023-08-30Purchasedirector
41,026
0.1145%
$1.31$53,744-19.77%
2023-08-17Purchasedirector
24,766
0.0684%
$1.29$31,948-17.32%
2023-08-16Purchasedirector
117,348
0.323%
$1.29$151,379-18.22%
2023-08-15Purchasedirector
107,886
0.3087%
$1.32$142,410-16.54%

Insider Historical Profitability

23.94%
Lamond Daviddirector
2347545
5.4245%
$1.46140
Thye DirkCEO AND CHIEF MEDICAL OFFICER
843941
1.9501%
$1.4640
Hannah BrendanCHIEF BUSINESS OFFICER AND COO
296540
0.6852%
$1.4640
Ryan Charles S.PRESIDENT
122461
0.283%
$1.4610
EPIQ Capital Group, LLC
2860967
6.6109%
$1.46100+23.94%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Tang Capital Management, LLC$3.12M6.822.95M-8.46%-$288,688.870.01
The Vanguard Group$1.2M2.621.13M+16.44%+$169,312.77<0.0001
EPIQ Capital Group$896,519.001.96845,773-2.8%-$25,821.590.36
Renaissance Technologies$551,000.001.2520,100+13.39%+$65,069.06<0.01
BlackRock$352,010.000.77332,086-1.05%-$3,729.07<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.